Cargando…
Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress
OBJECTIVE: To investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of colorectal cancer (CRC) and to analyze the effects on brain peptides, intestinal flora, and oxidative stress in CRC patients. METHODS: Eighty two patients with CRC who were admitted to our hospital f...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035672/ https://www.ncbi.nlm.nih.gov/pubmed/35478726 http://dx.doi.org/10.3389/fsurg.2022.872112 |
_version_ | 1784693347374333952 |
---|---|
author | Chen, Chao Hou, Songtao Zhao, Fei Wu, Bin Liu, Tingting Zhang, Zhao Li, Yuwei Li, Hongchao |
author_facet | Chen, Chao Hou, Songtao Zhao, Fei Wu, Bin Liu, Tingting Zhang, Zhao Li, Yuwei Li, Hongchao |
author_sort | Chen, Chao |
collection | PubMed |
description | OBJECTIVE: To investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of colorectal cancer (CRC) and to analyze the effects on brain peptides, intestinal flora, and oxidative stress in CRC patients. METHODS: Eighty two patients with CRC who were admitted to our hospital from March 2018 to June 2021 were selected as the research subjects and divided into the control group (n = 41) and the observation group (n = 41). The control group was treated with XELOX chemotherapy, and the observation group was additionally treated with bevacizumab, which was repeated every 3 weeks for a total of two treatments. The therapeutic effects of the two groups were evaluated after treatment. The brain-gut peptide index, intestinal flora index and oxidative stress index were detected, and the adverse reactions of the two groups were recorded. RESULTS: In the control group, ER was 36.59% (15/41) and DCR was 73.17% (30/41). In the observation group, ER was 63.41% (26/41) and DCR was 90.24% (37/41). ER and DCR in the observation group were higher than those in the control group (P < 0.05). After treatment, the levels of motilin and gastrin in the observation group were lower than those in the control group, and ghrelin was higher than that in the control group (P < 0.05). After treatment, the levels of Bifidobacterium, Lactobacilli and Enterococcus in the observation group were higher than those in the control group, and the level of Escherichia coli was lower than that in the control group (P < 0.05). After treatment, the SOD level of the observation group was lower than that of the control group, and the MDA level was higher than that of the control group. CONCLUSION: Bevacizumab combined with chemotherapy has good efficacy in the treatment of colorectal cancer patients, which can effectively improve the gastrointestinal motility of patients, regulate the intestinal flora of the body, rebuild the microecological balance, effectively reduce the oxidative stress response of patients, and reduce the incidence of adverse reactions. |
format | Online Article Text |
id | pubmed-9035672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90356722022-04-26 Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress Chen, Chao Hou, Songtao Zhao, Fei Wu, Bin Liu, Tingting Zhang, Zhao Li, Yuwei Li, Hongchao Front Surg Surgery OBJECTIVE: To investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of colorectal cancer (CRC) and to analyze the effects on brain peptides, intestinal flora, and oxidative stress in CRC patients. METHODS: Eighty two patients with CRC who were admitted to our hospital from March 2018 to June 2021 were selected as the research subjects and divided into the control group (n = 41) and the observation group (n = 41). The control group was treated with XELOX chemotherapy, and the observation group was additionally treated with bevacizumab, which was repeated every 3 weeks for a total of two treatments. The therapeutic effects of the two groups were evaluated after treatment. The brain-gut peptide index, intestinal flora index and oxidative stress index were detected, and the adverse reactions of the two groups were recorded. RESULTS: In the control group, ER was 36.59% (15/41) and DCR was 73.17% (30/41). In the observation group, ER was 63.41% (26/41) and DCR was 90.24% (37/41). ER and DCR in the observation group were higher than those in the control group (P < 0.05). After treatment, the levels of motilin and gastrin in the observation group were lower than those in the control group, and ghrelin was higher than that in the control group (P < 0.05). After treatment, the levels of Bifidobacterium, Lactobacilli and Enterococcus in the observation group were higher than those in the control group, and the level of Escherichia coli was lower than that in the control group (P < 0.05). After treatment, the SOD level of the observation group was lower than that of the control group, and the MDA level was higher than that of the control group. CONCLUSION: Bevacizumab combined with chemotherapy has good efficacy in the treatment of colorectal cancer patients, which can effectively improve the gastrointestinal motility of patients, regulate the intestinal flora of the body, rebuild the microecological balance, effectively reduce the oxidative stress response of patients, and reduce the incidence of adverse reactions. Frontiers Media S.A. 2022-04-11 /pmc/articles/PMC9035672/ /pubmed/35478726 http://dx.doi.org/10.3389/fsurg.2022.872112 Text en Copyright © 2022 Chen, Hou, Zhao, Wu, Liu, Zhang, Li and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Surgery Chen, Chao Hou, Songtao Zhao, Fei Wu, Bin Liu, Tingting Zhang, Zhao Li, Yuwei Li, Hongchao Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress |
title | Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress |
title_full | Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress |
title_fullStr | Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress |
title_full_unstemmed | Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress |
title_short | Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress |
title_sort | application of bevacizumab combined with chemotherapy in patients with colorectal cancer and its effects on brain-gut peptides, intestinal flora, and oxidative stress |
topic | Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035672/ https://www.ncbi.nlm.nih.gov/pubmed/35478726 http://dx.doi.org/10.3389/fsurg.2022.872112 |
work_keys_str_mv | AT chenchao applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress AT housongtao applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress AT zhaofei applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress AT wubin applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress AT liutingting applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress AT zhangzhao applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress AT liyuwei applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress AT lihongchao applicationofbevacizumabcombinedwithchemotherapyinpatientswithcolorectalcanceranditseffectsonbraingutpeptidesintestinalfloraandoxidativestress |